Ghada ShoushaAin Shams University, Egypt
Title: The updates in atopic dermatitis management
Atopic dermatitis prevalence and severity are increasing worldwide with progressive negative impact on the quality of life of patients, particularly the pediatric age group. Type 2 inflammation has been widely explored in the recent years as a predominant underlying pathogenesis. Therefore, new modalities of treatment, both topical and systemic, have been emerged over the past 10 years, including the biological therapies. When and how to use these advanced lines of treatment are needed to be understood. Benefit versus risk should be weighted for each particular patient. The impact of different advanced therapies on atopic dermatitis subjective and objective severity was recorded.
Ghada Shousha has completed her MD in Pediatrics at the age of 35 years from Ain Shams University, Egypt. She is a consultant of Pediatric Allergy, Immunology and Rheumatology since 2018. She has 15 publications in her field and has participated in multiple international and national conferences. She is an active member in World Allergy Organization (WAO), European Academy of Allergy and Clinical Immunology (EAACI), European Society of Immunodeficiency (ESID), The Pediatric Rheumatology International Trials Organization (PRINTO) and The Egyptian Society of Pediatric Allergy and Immunology (ESPAI), which is a center of excellence